Clinical trial
Prospective, Open-Label, Multicenter, International Study of Mifepristone for…
NCT00422201 · HRA Pharma, Industry · Terminated
Key facts
| NCT number | NCT00422201 |
|---|---|
| Title | Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion |
| Official title | Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion |
| Lead sponsor | HRA Pharma, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cushing's Syndrome |
| Intervention type | Drug |
| Interventions | Mifepristone |
| Enrollment | 18 |
| Start date | May 15, 2007 |
| Primary completion | Apr 4, 2012 |
| Completion | Apr 4, 2012 |
| First posted | Jan 15, 2007 |
| Last update posted | Oct 11, 2019 |
| Countries | France, Germany, Italy, Netherlands, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: